
UpTrajectory Review
Snack giants now face a double squeeze: inflation fatigue and the rapid rise of GLP-1 appetite-suppressing drugs. The University of Illinois study cited in the piece reports that GLP-1 users spend significantly less at the grocery store, shifting away from snacks, alcohol, and carbohydrates toward high-protein and nutrient-dense foods. Forbes estimates 10 million Americans used GLP-1s in 2025 and projects 25 million by 2030. At the same time, SNAC International data shows inflation-weary consumers abandoning major name brands for cheaper private label options. Campbell's, the company behind Goldfish and Late July, reported third quarter fiscal 2026 net sales of $2.37 billion, down 4% year-over-year, with salty snacks retail sales declining 6.2% and chips consumption dropping 4.5%. CEO Mick Beekhuizen stated the results reflect top-line softness and inflation-driven margin headwinds, and hinted some snacks might soon disappear from the portfolio.
For a small-business operator, this is not just a story about big food brands. If you run a café, convenience store, vending operation, or any retail outlet that stocks packaged snacks, your category mix may need a rethink. The shift toward high-protein and nutrient-dense options is measurable and growing. GLP-1 adoption is projected to more than double by 2030, meaning the customer who once grabbed a bag of chips may now reach for a protein bar or a small, protein-forward meal. Operators who stock shelves based on last year's sales data risk carrying inventory that moves slower each quarter. The private label surge also signals that price sensitivity remains acute: customers are trading down, and they expect value.
What is genuinely new here is the explicit link between GLP-1 adoption and snack category decline. Most coverage of GLP-1s focuses on healthcare or weight loss; this piece connects the drugs to grocery basket composition and forces consumer packaged goods companies to confront a structural demand shift, not a cyclical dip. We agree with the piece's framing that this is a dual pressure: inflation fatigue is real, but the GLP-1 effect is a separate, longer-term force. Where we are skeptical is the speed of the impact. The 25 million projection for 2030 is an estimate, and drug adoption depends on insurance coverage, side effects, and supply. The snack decline may be more gradual than the headline implies, but the direction is clear.
The second-order effects reach beyond snack aisles. Beverage makers, alcohol brands, and carbohydrate-heavy categories face the same headwind. Retailers who rely on snack traffic for impulse purchases may see basket sizes shrink. On the cost side, Campbell's and its peers will likely respond with SKU rationalization, meaning fewer product variants on shelves. That creates shelf space for smaller brands and private label entrants. Operators who source directly from regional snack producers or who develop their own branded protein-forward options may find openings that did not exist two years ago. The pressure on margins also means trade spend and promotional support from big brands may shift, altering the economics of stocking decisions.
Watch Campbell's next earnings call for concrete details on which snack lines face cuts, and monitor whether other packaged food companies follow with similar warnings. Operators should audit their snack and beverage mix now: track which items are turning slower, test high-protein and nutrient-dense alternatives in a small set of locations, and compare private label sell-through against national brands. If you operate a food service business, consider adding small-portion, protein-forward menu items that align with the GLP-1 user profile. The operators who adjust their assortment early will capture the shift; those who wait will carry the cost of stale inventory.
“Early evidence suggests that individuals using GLP-1s spend significantly less money at the grocery store, shifting their purchasing habits away from snacks, alcohol, and carbohydrates.” — TheStreet
Takeaway: Audit your snack and beverage mix now: shift shelf space toward high-protein, nutrient-dense options and test private label to match changing customer habits.
Excerpt from the original — TheStreet
Snacks have completely different meanings for kids and adults. When we are small, it’s something tasty that we are not allowed to have every day, making it even more delicious. As adults, it’s nostalgia for those innocent times when we could find true happiness in a bag of chips. However, the nostalgia play is becoming more challenging for the packaged goods companies as inflation fatigue and the rapid rise of appetite-suppressing GLP-1 medication affect its sales. “Early evidence suggests that individuals using GLP-1s spend significantly less money at the grocery store, shifting their purchasing habits away from snacks, alcohol, and carbohydrates while also increasing demand for high-protein and nutrient-dense foods,” according to a University of Illinois study. In 2025, about 10 million Americans have used GLP-1 medications, and that number is estimated to reach 25 million in 2030 …